cardiac toxicity assessment using stem cell derived cardiomyocytes
Published 10 years ago • 946 plays • Length 49:20Download video MP4
Download video MP3
Similar videos
-
1:15
cardiotoxicity screening using hipsc cardiomyocytes and acea's xcelligence cardioecr sysem
-
57:01
webinar: exploring the role of ipsc-cardiomyocytes in drug discovery and safety assessment
-
19:39
unraveling kinase inhibitor cardiotoxicity with cardiomyocyte impedance assays
-
7:10
innovations series with acea bioscience's xcelligence cardioecr system
-
53:40
utilizing stem cell-derived cardiomyocytes for early safety screening - webinar presentation
-
24:26
icell® cardiomyocytes & cardiotoxicity assessment
-
36:26
xcelligence® rtca cardioecr system
-
28:27
innovations w/ed begley, jr featuring acea's rtca xcelligence cardioecr system- intv1218
-
6:51
massive expansion and biobanking of stem cell derived cardiomyocytes | umc utrecht
-
24:33
evaluating drug induced proarrhythmic risk using the cardioecr system
-
1:01:00
predictive human induced pluripotent stem cell-derived cardiomyocyte model of cardiotoxicity
-
14:16
ipsc derived cardiomyocytes for predicting and removing drug cardiotoxicity - mark mercola
-
0:19
ipsc cardiomyocytes beating in a e plate
-
57:01
exploring the role of ipsc-cardiomyocytes in drug discovery and safety assessment
-
36:16
ipscs for cardiovascular diseases
-
49:26
harnessing ipsc-derived cardiac progenitor cells and fibroblasts for myocardial repair
-
39:49
using human stem cell-derived cardiomyocytes to investigate in vitro human cardiomyocyte biology
-
45:56
xcelligence training